<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543439</url>
  </required_header>
  <id_info>
    <org_study_id>3082B2-313</org_study_id>
    <secondary_id>B1831001</secondary_id>
    <secondary_id>2006-005575-17</secondary_id>
    <nct_id>NCT00543439</nct_id>
  </id_info>
  <brief_title>Study Evaluating Prophylaxis Treatment &amp; Characterizing Efficacy, Safety, &amp; PK Of B-Domain Deleted Recombinant FVIII</brief_title>
  <official_title>An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the effectiveness, safety, and
      pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are
      younger than 6 years of age, with severe or moderately severe hemophilia A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2007</start_date>
  <completion_date type="Actual">April 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The annualized bleed rate is the primary endpoint for testing the primary objective of the study (comparing prophylaxis to on-demand therapy)</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The annualized bleed rate is the endpoint for testing one of the secondary objectives (comparing high vs low frequency prophylaxis regimens).</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of moroctocog alfa (AF-CC) infusions per bleed</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of bleed to moroctocog alfa (AF-CC) treatment (4-point scale of assessment)</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval between bleed onset and prior moroctocog alfa (AF-CC) prophylaxis dose</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of prophylaxis regimen escalation</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Less than Expected Therapeutic Effect</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of moroctocog alfa (AF-CC)</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with assigned prophylaxis regimen</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed FVIII inhibitor development</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine Prophylaxis Crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Moroctocog alfa (AF-CC)</intervention_name>
    <description>On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xyntha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Moroctocog alfa (AF-CC)</intervention_name>
    <description>Routine prophylaxis crossover:
45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Xyntha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects, aged less than 6 years, with moderately severe to severe hemophilia A.

          -  A negative FVIII inhibitor titer at screening, and a medical history negative for a
             past FVIII inhibitor.

          -  At least 20 exposure days to any FVIII replacement product.

          -  Adequate hepatic and renal function

          -  CD4 count &gt; 400 cells/uL, and if receiving antiviral therapy must be on a stable
             regimen

        Additional criteria for subjects participating in the PK assessment:

          -  Male subjects as described immediately above except they must have a FVIII Activity of
             less than or equal to 1% confirmed by the central laboratory screening test

          -  Age &lt; 6 years at time of PK assessment.

          -  The subject's size is sufficient to permit PK-related phlebotomy.

          -  The subject is able to comply with the procedures conducted during the PK assessment,
             including a mandatory 72-hour washout period preceding the PK assessment.

        Exclusion Criteria:

          -  A history of FVIII inhibitor.

          -  Presence of a bleeding disorder in addition to hemophilia A.

          -  Treatment with any investigational drug or device within 30 days before the time of
             signing the informed consent form.

          -  Major or orthopedic surgery planned to occur during the course of the study.

          -  Regular (e.g., daily, every other day) use of antifibrinolytic agents or medications
             known to influence platelet function such as aspirin or certain nonsteroidal
             anti-inflammatory drugs (NSAIDs), or regular, concomitant therapy with
             immunomodulating drugs (e.g., intravenous immunoglobulin [IVIG], routine systemic
             corticosteroids).

          -  Known hypersensitivity to hamster protein.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Investigational Pharmacy</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de la Hemofilia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BWE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liga Colombiana de Hemofílicos y otras Deficiencias Sanguíneas</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan University of Science and Technology, King Abdullah University Hospital</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Dr. Juan I. Menchaca</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital y Clinica OCA S.A. de C.V.</name>
      <address>
        <city>Colonia Centro</city>
        <state>Monterrey, Nuevo LEON</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <state>South Island</state>
        <zip>8001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canterbury District Health Board</name>
      <address>
        <city>Christchurch</city>
        <zip>8001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sultan Qaboos University Hospital</name>
      <address>
        <city>Muscat</city>
        <zip>123</zip>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Monte Carmelo</name>
      <address>
        <city>Urbanización La Victoria</city>
        <state>Arequipa</state>
        <zip>054</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Dzieciecy Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <zip>00-576</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanador</name>
      <address>
        <city>Bucuresti</city>
        <zip>011026</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Tip Fakultesi</name>
      <address>
        <city>Balcali/Adana</city>
        <state>Adana</state>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Cocuk Hastanesi</name>
      <address>
        <city>Izmir</city>
        <state>Bornova</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universtesi Istanbul Tip Fakultesi</name>
      <address>
        <city>Capa</city>
        <state>Istanbul</state>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>On Dokuz Mayis University Faculty of Medicine</name>
      <address>
        <city>Samsun</city>
        <state>Kurupelit</state>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi Tip Fakultesi</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Behcet Uz Child and Diseases And Surgery Education and Research Hospital</name>
      <address>
        <city>Izmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes Universitesi Tip Fakultesi</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Jordan</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Oman</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3082B2-313&amp;StudyName=Study%20Evaluating%20Prophylaxis%20Treatment%20%26%20Characterizing%20Efficacy%2C%20Safety%2C%20%26%20PK%20Of%20B-Domain%20Deleted%20Recombinant%20FVIII</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

